相关实验视频

Updated: Jan 7, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

骨髓海绵和慢性疼痛:对于脏缩有没有作用?

Fatima Ayotunde¹, David S Goldfarb²

¹Division of Nephrology, NYU Langone Health and NYU Grossman School of Medicine.

Current opinion in nephrology and hypertension

|December 29, 2025

概括

骨髓海绵 (MSK) 患者经常遭受严重的慢性疼痛,对标准治疗没有反应. 脏皮表现出管理这种令人虚弱的疼痛和改善生活质量的前景.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
疼痛医学医学疼痛医学
干预心脏病学干预心脏病学

背景情况:

骨髓海绵 (MSK) 是一种先天性管管疾病,导致结石和严重的慢性疼痛.
目前的MSK疼痛管理往往不足,治疗选择有限.
在MSK中慢性疼痛的病因通常不清楚,并且独立于尿路阻塞.

研究的目的:

审查脏缩在与状海绵脏相关的慢性疼痛管理中的作用.
解决MSK患者治疗严重疼痛综合征的治疗缺口.

主要方法:

审查关于髓海绵脏和慢性疼痛管理的现有文献.
探索在MSK患者中脏变色的潜在应用.
在其他慢性疼痛疾病中分析损的效用.

主要成果:

脏缩是缓解MSK慢性脏疼痛的潜在策略.
这种干预可以带来显著的疼痛缓解和提高患者的生活质量.

结论:

对于MSK的最佳慢性疼痛管理策略仍未确定.
最近被批准用于高血压的脏缩可能为MSK相关的慢性疼痛提供新的治疗途径.

关键词:

卡奇 - 里奇综合征是卡奇 - 里奇综合征.慢性疼痛是一种慢性疼痛.诊断成像诊断成像的使用.骨髓灰质炎是一种神经病.脏结肠发作脏结肠发作尿病是一种尿病.

更多相关视频

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.

Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.

Published on: February 14, 2018

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...